المؤلفون: Debbie van Baarle, Nynke Y. Rots, Mathilda Jalving, Christian U. Blank, Elisabeth G.E. de Vries, Guus F. Rimmelzwaan, Tatjana T Westphal, Cecile A C M van Els, Anne-Marie C. Dingemans, John B. A. G. Haanen, T. Jeroen N. Hiltermann, Egbert F. Smit, Rudolf S N Fehrmann, Arkajyoti Bhattacharya, Rob van Binnendijk, Astrid A M van der Veldt, Gerco den Hartog, Anke Huckriede, Pia Kvistborg, Corine H. GeurtsvanKessel, Sjoukje F. Oosting, Marion Koopmans, Marieke van der Heiden

المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Translational Immunology Groningen (TRIGR), Targeted Gynaecologic Oncology (TARGON), Microbes in Health and Disease (MHD), Medical Oncology, Radiology & Nuclear Medicine, Virology, Pulmonary Medicine

المصدر: Lancet Oncology, 22(12), 1681-1691. ELSEVIER SCIENCE INC
The Lancet Oncology, 22(12), 1681-1691. Lancet Publishing Group
The Lancet. Oncology

مصطلحات موضوعية: Male, medicine.medical_specialty, Antineoplastic Agents, Antibodies, Viral, Injections, Intramuscular, Cohort Studies, Immunomodulation, Interferon-gamma, Immunogenicity, Vaccine, SDG 3 - Good Health and Well-being, Chemoimmunotherapy, Neoplasms, Surveys and Questionnaires, VACCINES, Internal medicine, medicine, Clinical endpoint, Humans, Prospective Studies, Seroconversion, Adverse effect, Aged, Netherlands, SARS-CoV-2, business.industry, Vaccination, COVID-19, Cancer, Articles, Middle Aged, medicine.disease, Combined Modality Therapy, CANCER, Oncology, Cohort, Female, Immunotherapy, business, Febrile neutropenia, 2019-nCoV Vaccine mRNA-1273, RESPONSES

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b729685410a8953022f09c2f02822a62Test
https://doi.org/10.1016/s1470-2045Test(21)00574-x

المؤلفون: Alfonsus J. M. van den Eertwegh, Michel W.J.M. Wouters, Roos S. van Rijn, John B. A. G. Haanen, Maureen J.B. Aarts, Bert-Jan J. ten Tije, Karijn P M Suijkerbuijk, Christian U. Blank, Jesper van Breeschoten, Geke A. P. Hospers, Jan-Willem B de Groot, Franchette W P J van den Berkmortel, Ellen Kapiteijn, Doranne L. Hilarius, Marye J Boers-Sonderen, Djura Piersma, Art Vreugdenhil, Astrid A M van der Veldt, Willeke A. M. Blokx

المساهمون: VU University medical center, Obstetrics and gynaecology, Internal medicine, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, Radiology & Nuclear Medicine, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9)

المصدر: British Journal of Cancer
British Journal of Cancer, 124(7), 1222-1230. Nature Publishing Group
British Journal of Cancer, 124, 7, pp. 1222-1230
British Journal of Cancer, 124, 1222-1230
van Breeschoten, J, Wouters, M W J M, Hilarius, D L, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J-W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, Blokx, W A M, Tije, B-J J T, Veldt, A A M V D, Vreugdenhil, A, Boers-Sonderen, M J & van den Eertwegh, A J M 2021, ' First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis ', British Journal of Cancer, vol. 124, no. 7, pp. 1222-1230 . https://doi.org/10.1038/s41416-020-01229-1Test
British Journal of Cancer, 124(7), 1222-1230. SPRINGERNATURE

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, PHASE-3, First line, Systemic therapy, VEMURAFENIB, Article, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], POOLED ANALYSIS, Matched cohort, SDG 3 - Good Health and Well-being, Internal medicine, Medicine, METASTATIC MELANOMA, neoplasms, Melanoma, Survival analysis, Advanced melanoma, nivolumab, business.industry, IPILIMUMAB, Anti pd 1, medicine.disease, DABRAFENIB, Propensity score matching, pembrolizumab, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::836391be4c5b8d33487fc86cac6f6337Test
https://doi.org/10.1038/s41416-020-01229-1Test

المؤلفون: Maurits L. van Montfoort, Daniel J. Vis, Kees Hendricksen, Nick van Dijk, Laura A. Smit, Michiel S. van der Heijden, Henk G. van der Poel, Maries van den Broek, Christian U. Blank, Annemarie Bruining, Yoni Lubeck, Lodewyk F. A. Wessels, Dennis Peters, Pia Kvistborg, Karina Silina, Ton N. Schumacher, Charlotte van Rooijen, Karolina Sikorska, Erik Hooijberg, Annegien Broeks, Bas W.G. van Rhijn, Alberto Gil-Jimenez, Jeantine M de Feijter, Thierry N. Boellaard

المساهمون: University of Zurich, van der Heijden, Michiel S, Graduate School

المصدر: Nature medicine, 26(12), 1839-1844. Nature Publishing Group

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, medicine.medical_specialty, medicine.medical_treatment, Programmed Cell Death 1 Receptor, 610 Medicine & health, Ipilimumab, 10263 Institute of Experimental Immunology, Gastroenterology, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, 1300 General Biochemistry, Genetics and Molecular Biology, Neoplasms, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Humans, Medicine, CTLA-4 Antigen, Stage (cooking), Adverse effect, Aged, Neoplasm Staging, business.industry, Antibodies, Monoclonal, General Medicine, Immunotherapy, Middle Aged, Clinical trial, Nivolumab, 030104 developmental biology, 030220 oncology & carcinogenesis, Monoclonal, 570 Life sciences, biology, Female, Urothelium, business, medicine.drug

وصف الملف: 2020_van_Dijk_Nat_Med.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0413d513e2c90df2d190163c39a4236dTest
http://www.scopus.com/inward/record.url?scp=85092396181&partnerID=8YFLogxKTest

المؤلفون: Christian U. Blank, Maureen J.B. Aarts, Djura Piersma, Karijn P M Suijkerbuijk, Franchette W P J van den Berkmortel, Michel W.J.M. Wouters, Geke A. P. Hospers, Astrid Aplonia Maria Van Der Veldt, Anne M.L. Jansen, Han J. Bonenkamp, Marye Boers-Sonderen, Jan Willem B. de Groot, John B. A. G. Haanen, Rozemarijn S. van Rijn, Alfonsus J. M. van den Eertwegh, Marion Stevense, Ellen Kapiteijn, Willeke A. M. Blokx, Gerard Vreugdenhil, Olivier Jules van Not

المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS)

المصدر: Journal of Clinical Oncology, 39(15). AMER SOC CLINICAL ONCOLOGY

مصطلحات موضوعية: Neuroblastoma RAS viral oncogene homolog, Cancer Research, Oncology, business.industry, Immune checkpoint inhibitors, Mutation (genetic algorithm), Cancer research, Medicine, business, neoplasms, Gene, Advanced melanoma

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed303bc2f6f7ffdcf827c043b9870b03Test
https://research.rug.nl/en/publications/4d75de12-c696-44ea-b920-33c203f7113aTest

المؤلفون: Astrid A M, van der Veldt, Sjoukje F, Oosting, Anne-Marie C, Dingemans, Rudolf S N, Fehrmann, Corine, GeurtsvanKessel, Mathilde, Jalving, Guus F, Rimmelzwaan, Pia, Kvistborg, Christian U, Blank, Egbert F, Smit, Valery E E P, Lemmens, T Jeroen N, Hiltermann, Marion P G, Koopmans, Anke L W, Huckriede, Nynke Y, Rots, Cecile A C M, van Els, Debbie, van Baarle, John B A G, Haanen, Elisabeth G E, de Vries

المصدر: Nature medicine. 27(4)

مصطلحات موضوعية: COVID-19 Vaccines, SARS-CoV-2, Neoplasms, Vaccination, COVID-19, Humans, Longitudinal Studies, Prospective Studies, Antibodies, Viral

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid________::13605f01f94c2adf9624f374c2b7397dTest
https://pubmed.ncbi.nlm.nih.gov/33589821Test

المؤلفون: Jan-Willem B de Groot, Christian U. Blank, Doranne H Hilarius, Liesbeth C. de Wreede, Astrid A.M. van der Veldt, Djura Piersma, Ellen Kapiteijn, Franchette W P J van den Berkmortel, Geke A. P. Hospers, Rozemarijn S. van Rijn, Karijn P M Suijkerbuijk, Marye J Boers, Gerard Vreugdenhil, Michel W.J.M. Wouters, Albert J. ten Tije, John B. A. G. Haanen, Maureen J.B. Aarts, Alfons J.M. van den Eertwegh, Willeke A M Blokx, Jesper van Breeschoten

المساهمون: Radiology & Nuclear Medicine, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Obstetrics and gynaecology, Internal medicine, AII - Cancer immunology, CCA - Cancer biology and immunology, CCA - Cancer Treatment and quality of life, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9)

المصدر: van Breeschoten, J, Wouters, M W J M, de Wreede, L C, Hilarius, D H, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J-W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, Blokx, W A M, ten Tije, A J, van der Veldt, A A M, Vreugdenhil, G, Boers, M J & van den Eertwegh, A J M 2021, ' Nationwide Outcomes of Advanced Melanoma According to BRAFV600Status ', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 44, no. 2, pp. 82-89 . https://doi.org/10.1097/COC.0000000000000786Test
American Journal of Clinical Oncology-Cancer Clinical Trials, 44(2), 82-89. Lippincott Williams & Wilkins
American Journal of Clinical Oncology, 44, 82-89
American Journal of Clinical Oncology, 44, 2, pp. 82-89
American journal of clinical oncology-Cancer clinical trials, 44(2), 82-89. LIPPINCOTT WILLIAMS & WILKINS
American Journal of Clinical Oncology: Cancer Clinical Trials, 44(2), 82-89. Lippincott Williams and Wilkins Ltd.
American Journal of Clinical Oncology, 44(2), 82-89. LIPPINCOTT WILLIAMS & WILKINS
American Journal of Clinical Oncology-Cancer Clinical Trials, 44(2), 82-89. LIPPINCOTT WILLIAMS & WILKINS

مصطلحات موضوعية: Male, Proto-Oncogene Proteins B-raf, advanced melanoma, Cancer Research, medicine.medical_specialty, Immune checkpoint inhibitors, Kaplan-Meier Estimate, B7-H1 Antigen, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], BRAF, 03 medical and health sciences, 0302 clinical medicine, All institutes and research themes of the Radboud University Medical Center, SDG 3 - Good Health and Well-being, Internal medicine, anti-PD-1-ligands, Antineoplastic Combined Chemotherapy Protocols, Overall survival, medicine, Humans, Stage IIIC, CTLA-4 inhibitor, Longitudinal Studies, 030212 general & internal medicine, Melanoma, neoplasms, MEK inhibitors, Aged, Netherlands, Proportional Hazards Models, Advanced melanoma, Aged, 80 and over, Brain Neoplasms, business.industry, National Registry, Hazard ratio, Treatment options, medicine.disease, Confidence interval, Survival Rate, BRAF mutation, Oncology, 030220 oncology & carcinogenesis, Mutation, Female, business, checkpoint inhibitors

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::837893c187a1176e5ed3c58a137cf6f2Test
https://research.vumc.nl/en/publications/09c72104-8257-4b6c-89da-5dc441a033f4Test

المؤلفون: Christian U. Blank, Elisa A. Rozeman

المصدر: Nature Medicine. 25:879-882

مصطلحات موضوعية: 0301 basic medicine, endocrine system diseases, business.industry, medicine.medical_treatment, Melanoma, Immune checkpoint inhibitors, Cancer therapy, General Medicine, Immunotherapy, medicine.disease, digestive system diseases, General Biochemistry, Genetics and Molecular Biology, Targeted therapy, Proto-Oncogene Proteins B-raf, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Text mining, Cancer immunotherapy, 030220 oncology & carcinogenesis, Cancer research, Medicine, business, neoplasms

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::64d57875d9ebe9379b487682e9285000Test
https://doi.org/10.1038/s41591-019-0482-7Test

المؤلفون: Ieva Kurilova, Regina G. H. Beets-Tan, Ferry Lalezari, S.G. Drago, A. Delli Pizzi, J.B.A.G. Haanen, Chintan Parmar, Maartje W. Rohaan, Stefano Trebeschi, Doenja M. J. Lambregts, Elisa A. Rozeman, Egbert F. Smit, Nicolai Juul Birkbak, Koen J. Hartemink, A.M. Cǎlin, Charles Swanton, Christian U. Blank, Hugo J.W.L. Aerts

المساهمون: Promovendi ODB, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Faculteit FHML Centraal

المصدر: Trebeschi, S, Drago, S G, Birkbak, N J, Kurilova, I, Cǎlin, A M, Delli Pizzi, A, Lalezari, F, Lambregts, D M J, Rohaan, M W, Parmar, C, Rozeman, E A, Hartemink, K J, Swanton, C, Haanen, J B A G, Blank, C U, Smit, E F, Beets-Tan, R G H & Aerts, H J W L 2019, ' Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers ', Annals of Oncology, vol. 30, no. 6, mdz108, pp. 998-1004 . https://doi.org/10.1093/annonc/mdz108Test
Technology in Cancer Research & Treatment
Annals of Oncology, 30(6), 998-1004. Oxford University Press
Annals of Oncology

مصطلحات موضوعية: 0301 basic medicine, Oncology, SELECTION, Lung Neoplasms, BLOCKADE, medicine.medical_treatment, FEATURES, Programmed Cell Death 1 Receptor, 0302 clinical medicine, Cancer immunotherapy, Neoplasms, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, PD-1, Melanoma, Letter to the Editor, DOCETAXEL, RISK, Special Collection on Current Technologies in Targeted Cancer Immunotherapies, Hematology, Prognosis, artificial intelligence, 3. Good health, Survival Rate, machine learning, radiomics, 030220 oncology & carcinogenesis, Biomarker (medicine), immunotherapy, SENSITIVITY, Algorithms, EXPRESSION, medicine.medical_specialty, CELL LUNG-CANCER, medical imaging, 03 medical and health sciences, Onco-Immunology, Predictive Value of Tests, Internal medicine, medicine, Medical imaging, Immunologic Factors, Humans, Lung cancer, SIGNATURES, Noninvasive biomarkers, business.industry, Cancer, NIVOLUMAB, Immunotherapy, medicine.disease, Original articles, Editor's Choice, 030104 developmental biology, response prediction, business, Tomography, X-Ray Computed, Biomarkers, Follow-Up Studies

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fd03537dc5d67fb40abb417868a1cc9Test
https://doi.org/10.1093/annonc/mdz108Test

المؤلفون: Astrid A M van der Veldt, Karijn P M Suijkerbuijk, Christian Menzer, Lisa Zimmer, Thomas Eigentler, Alexander Enk, Richard F. Kefford, K. H. Herbschleb, Georgina V. Long, Christian U. Blank, Alexander M. Menzies, Jessica C. Hassel, Max Schlaak, Frank Meiss, Friedegund Meier, Kai Martin Thoms, Irene L.M. Reijers, Thomas Haalck, Jonas Leichsenring, Bastian Schilling, Ralf Gutzmer, Alexander Menzer, Annette Kopp-Schneider, Jan Willem B. de Groot, Claudia Pföhler, Douglas B. Johnson, Matteo S. Carlino, Emma J. Groen, Hans M. Westgeest

المساهمون: Medical Oncology

المصدر: Journal of Clinical Oncology, 37(33), 3142-3151. American Society of Clinical Oncology
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 37(33), 3142. American Society of Clinical Oncology

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Medizin, medicine.disease_cause, Targeted therapy, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Journal Article, Medicine, Progression-free survival, neoplasms, Survival rate, Mutation, business.industry, MEK inhibitor, Melanoma, medicine.disease, 3. Good health, Regimen, 030104 developmental biology, 030220 oncology & carcinogenesis, business, V600E

وصف الملف: image/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcd8e106b84ce75482ab946f73d10d64Test
https://doi.org/10.1200/jco.19.00489Test

المؤلفون: Giampaolo Tortora, Bernard A. Fox, Ramy Ibrahim, Christian U. Blank, Alexander M.M. Eggermont, Michael Lahn, Anna Maria Di Giacomo, Michele Maio, R. Bryan Bell, Andrea Necchi

المساهمون: Maio, M., Blank, C., Necchi, A., Di Giacomo, A. M., Ibrahim, R., Lahn, M., Fox, B. A., Bell, R. B., Tortora, G., Eggermont, A. M. M.

مصطلحات موضوعية: 0301 basic medicine, Oncology, PD-L1, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Neoadjuvant trials, Biomarkers, Bladder cancer, CTLA-4, Head and neck cancer, Immunotherapy, Melanoma, Pancreatic cancer, PD-1, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, Internal medicine, Tumor Microenvironment, medicine, Humans, CTLA-4 Antigen, Immune Checkpoint Inhibitors, Lymph node, business.industry, Cancer, medicine.disease, Head and neck squamous-cell carcinoma, Neoadjuvant Therapy, 030104 developmental biology, medicine.anatomical_structure, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Adenocarcinoma, Neoplasm Recurrence, Local, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eba278732050d946d514842ba857bccaTest
https://hdl.handle.net/11365/1233299Test